# Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Source: https://onco.cc/trials/nct06500273/  
OnCo record `nct06500273` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fludarabine and Cyclophosphamide in diffuse large B-cell lymphoma, run by Allogene Therapeutics, now recruiting.

## Summary

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL is a phase 2 interventional study registered as NCT06500273 by Allogene Therapeutics, with 250 participants planned, started 2024-06-18 and due to reach its primary completion in 2027-12. Interventions recorded: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide and Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06500273
- Phase: 2
- Setting: A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
- Sponsor: Allogene Therapeutics
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT06500273: https://clinicaltrials.gov/study/NCT06500273

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)
- companies: [Allogene Therapeutics](https://onco.cc/companies/allogene/), [Foresight Diagnostics](https://onco.cc/companies/foresight-diagnostics/), [Natera](https://onco.cc/companies/natera/)

---
JSON: https://onco.cc/api/v1/entities/nct06500273.json